Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) CFO Karthik Radhakrishnan bought 1,550 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average cost of $16.25 per share, with a total value of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares in the company, valued at $25,187.50. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Monopar Therapeutics Stock Down 9.5 %
MNPR stock opened at $14.67 on Thursday. The stock’s 50 day moving average is $5.70 and its 200-day moving average is $4.19. Monopar Therapeutics Inc. has a twelve month low of $1.37 and a twelve month high of $38.50. The firm has a market capitalization of $51.64 million, a PE ratio of -6.38 and a beta of 1.26.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). On average, equities research analysts anticipate that Monopar Therapeutics Inc. will post -1.93 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on MNPR
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Read More
- Five stocks we like better than Monopar Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How to Invest in Blue Chip Stocks
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.